Table 4 Descriptive characteristics of patients with or without midazolam treatment during hospital stay
From: Emergency palliative cancer care: anxiety and midazolam
With midazolam treatment (n = 29) | Without midazolam treatment (n = 135) | |
|---|---|---|
Age, median [IQR] | 66.0 [58.0–73.0] | 73.0 [64.0–80.0] |
Gender, n (%) | ||
Male | 19 (65.5%) | 89 (65.9%) |
Female | 10 (34.5%) | 46 (34.1%) |
Social status, n (%) | ||
Living alone | 7 (24.1%) | 51 (37.8%) |
Married/cohabitant | 22 (75.9%) | 84 (62.2%) |
ECOG PS | ||
Score 1 | 2 (6.9%) | 15 (11.1%) |
Score 2 | 9 (31.0%) | 53 (39.3%) |
Score 3 | 14 (48.3%) | 62 (45.9%) |
Score 4 | 4 (13.8%) | 5 (3.7%) |
Anxiety at admission | ||
No anxiety | 5 (17.2%) | 40 (29.6%) |
Mild anxiety | 10 (34.5%) | 47 (34.8%) |
Moderate and severe anxiety | 14 (48.3%) | 48 (35.6%) |
Anxiety development during stay | ||
Deteriorated | 3 (10.3%) | 12 (8.9%) |
Stable | 17 (58.6%) | 88 (65.2%) |
Improved | 9 (31.0%) | 35 (25.9%) |
Pain development during stay | ||
Deteriorated | 3 (10.3%) | 13 (9.6%) |
Stable | 15 (51.7%) | 74 (54.8%) |
Improved | 11 (37.9%) | 48 (35.6%) |
Dyspnoea development during stay | ||
Deteriorated | 4 (13.8%) | 8 (5.9%) |
Stable | 20 (69.0%) | 85 (63.0%) |
Improved | 5 (17.2%) | 42 (31.1%) |
Midazolam dosage increase in mg/24 h, median [IQR] | 2.0 [2.0–6.0] | N/A |